Clinical Trials Browser

Phase 2 × Blastic Plasmacytoid Dendritic Cell Neoplasm × 90 days × Clear all

NCT03404193 2026-03-10

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04216524 2026-03-04

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Phase 2 Recruiting

40 enrolled

Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm